These studies include the CONFIDENCE study (NCT05254002), which evaluates the effect of finerenone in combination with the SGLT2 inhibitor empagliflozin on the relative change in UACR from baseline in participants with T2D and CKD [116]. Here, SLC5A2 is linked to type 2 diabetes mellitus.